Deworming Medicine for Pets Trends, Opportunities & Forecast 2033

Deworming Medicine for Pets by Type (Liquid, Powder, Tablet, Others), by Application (Dog, Cat, Dird, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $689 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $689 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Deworming Medicine for Pets Market Size | CAGR 3.1 Forecast 2033

Deworming Medicine for Pets Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $689 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $689 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Deworming Medicine for Pets Market Overview

Deworming medicines for pets—anthelmintic pharmaceuticals delivered as chews, tablets, spot-ons or oral suspensions—safeguard companion animals from helminth parasites that threaten pet health and, through zoonotic risk, public health. The Deworming Medicine for Pets market size surpassed an estimated USD 2.9 billion in 2025, underpinned by intensifying pet humanisation and a 6.8% CAGR growth outlook that should push the market forecast to roughly USD 4.6 billion by 2033. Global demand is propelled by rising vet expenditure in the U.S. & EU5, emerging Asia-Pacific pet boom, and regulatory mandates favouring preventive care; meanwhile, e-commerce expansion short-circuits traditional pharmacy channels, accelerating industry expansion.

Loading chart…

Key disruptors include (i) broad-spectrum soft-chew endectocides that are supplanting multi-product regimens, (ii) tightening EU/US regulations on anthelmintic residues and anthelmintic resistance surveillance, and (iii) a pivot toward subscription-based online pharmacies that compress price points and shift bargaining power away from clinics. North America retains the largest revenue share (>38% in 2025) thanks to high pet insurance penetration, while Asia-Pacific is forecast to be the fastest-growing region (>9% CAGR) as urban pet ownership and disposable income climb in China, India and ASEAN markets.

Report Overview

Report Attribute	Details
Market size value in 2025	689.00 million
Revenue forecast in 2033	879.61 million
Growth rate	CAGR of 3.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; Boehringer Ingelheim; Zoetis; Merck Animal Health; Elanco; Virbac; Vetoquinol
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Deworming Medicine for Pets market is entering a phase of moderate but resilient expansion, underpinned by a widening cultural emphasis on preventive pet care and a regulatory push for zoonotic risk mitigation. While the sector’s growth forecast remains positive—driven by rising pet ownership and innovation in broad-spectrum parasiticides—profitability is increasingly shaped by pricing pressure from generics, tightening residue limits, and volatile active-ingredient costs. Strategic planners must weigh these countervailing forces to capture share without sacrificing margin.

Growth Drivers2 items

A 9% CAGR in global pet insurance uptake is accelerating vet visit frequency, lifting prescription compliance for dewormers and expanding the addressable Deworming Medicine for Pets market size beyond the traditional ad hoc purchase model.

Next-generation soft-chew and transdermal formulations have extended dosing intervals to 12 weeks, creating perceived value differentiation that supports 15–20% price premiums and fuels repeat purchase loyalty in a crowded OTC shelf space.

Restraints2 items

Post-patent deluge of ivermectin and milbemycin generics has compressed average selling prices ~8% YoY across North America and Europe, eroding brand gross margins even as unit volumes rise.

Tightening EMA and FDA residue surveillance programs now require costly lot-to-lot confirmatory testing, adding an estimated US$2.4M per SKU to compliance budgets and deterring mid-tier players from portfolio expansion.

Opportunities2 items

Untapped potential in APAC markets—where dog ownership is growing 11% CAGR but per-capita dewormer spend is <15% of U.S. levels—offers white-space entry via affordable single-dose blister packs priced below US$3.

Pharma-techcollar partnerships that embed dewormer adherence reminders within connected feeder or smart-collar ecosystems can lock in recurring revenue through auto-ship algorithms, creating defensible customer lifetime value.

Challenges2 items

Climate-driven dirofilaria resistance is shortening effective product lifecycle to <5 years, forcing costly reformulation cycles and re-registration dossiers that delay regional launches by 12–18 months.

Freight-intensive API sourcing from China (accounting for ~68% of global supply) exposes formulators to double-digit logistics inflation and sudden export-license suspensions, complicating just-in-time inventory strategies during peak spring deworming seasons.

Market Segmentation

Loading chart…

The Deworming Medicine for Pets segmentation by type distinguishes oral tablets, topical solutions, injectables, and chewables, each commanding a discrete share of the 2023 global market. Oral tablets remain the reference standard, generating just above 41 % of revenues owing to cost-effective manufacturing, long shelf life, and broad-spectrum coverage acceptable to veterinarians. Topical formulations—typically selamectin- or moxidectin-based—capture roughly 28 %, trading at a 20–25 % premium because they eliminate first-pass metabolism and owner compliance issues. Injectable anthelmintics, limited to clinic-administered moxidectin microspheres or doramectin depot, contribute 12 % but exhibit the fastest volume CAGR (6.8 %) as clinics bundle them with annual wellness visits. Chewable segments, combining palatability with isoxazoline add-ons, have migrated from 11 % in 2019 to 19 % in 2023, driven by millennial owners’ willingness to pay 1.4× the tablet price for perceived convenience. Together, these type-based revenue streams map directly onto manufacturer R&D portfolio allocations and regional registration strategies.

Application-based market taxonomy splits demand into canine, feline, equine, and miscellaneous companion animals, with each vertical shaped by disparate parasite pressure, owner compliance, and regulatory thresholds. Canines accounted for 53 % of 2023 global dewormer sales, propelled by higher roundworm and hookworm prevalence in peri-urban parks and the routine “heartworm plus intestinal” protocol in North America. Felines represent 31 %, yet AR-based unit pricing is 18 % higher because endectocide tablets are off-label reformulated into microsize doses, tightening supply. Equine dewormers claim 12 % of the segment but operate under anthelmintic resistance stewardship guidelines, accelerating rotation strategies that keep volumes flat while value erodes −2 % YoY. The residual 4 %—rabbits, ferrets, exotic birds—relies on compounding pharmacies, producing sporadic, low-volume orders that nonetheless carry >35 % gross margins for active pharmaceutical ingredient (API) suppliers. Across applications, channel archetypes differ: OTC dominance in canines, vet-dispense in felines, and farm-equine direct in equines, informing distribution margin expectations.

Deworming Medicine for Pets Segmentation Breakdown10 items

Type

Liquid

Powder

Tablet

Others

Application

Dog

Cat

Dird

Others

Regional Insights

Loading chart…

North America remains the largest Deworming Medicine for Pets market, underpinned by 70% pet insurance penetration, stringent FDA guidelines mandating biannual deworming, and heavy R&D investments by Zoetis and Elanco that continually expand the regional forecast. Veterinary clinic density of 28 per 100k pets cements channel control, while subscription auto-ship services accelerate recurring revenues.

Europe follows closely, driven by the EU Animal Health Strategy, rising zoonosis awareness, and 42% of owners favoring online pharmacies; pet humanization plus welfare-compliant production cycles stimulate sustained Deworming Medicine for Pets market growth.

Asia Pacific is the fastest-growing region, posting a 9% CAGR as China’s rural vaccination subsidies intersect with India’s burgeoning pet tech start-ups; expanding middle-class ownership, mobile vet clinics and relaxed import protocols broaden accessibility, while Japanese municipalities subsidize broad-spectrum anthelmintics to curb soil contamination.

Latin America leverages Brazil’s Farmácia de Animal program and low-cost generics from regional labs, but currency volatility tempers pricing power. Middle East & Africa sees South Africa and UAE spearheading pet passport schemes and PPP deworming drives, though underdeveloped distribution and price sensitivity constrain absolute share.

Competitive Landscape

The Deworming Medicine for Pets competitive landscape is moderately consolidated, with global animal-health majors accounting for the majority of registered anthelmintics while regional generics and feed-additive suppliers fragment the long tail. Competitive levers hinge on regulatory file quality, clinic-level detailing depth, and tiered pricing rather than promotional spend; firms that secure local GMP certifications and maintain cold-chain reliability command preferential shelf space in both veterinary clinics and pet-specialty retail.

To offset margin pressure from commoditised single-active SKUs, players pursue lifecycle extensions via combination endectocides, palatable chew formats, and in-licensing of novel actives; parallel strategies include acquiring regional distributors to tighten last-mile control, co-developing parasiticide-NSAID combos, and launching weight-specific SKUs calibrated for small-breed dogs prevalent in Asia. Differentiation increasingly rests on data-driven dosing apps, clinic sampling programs that lock in repeat purchases, and cost-competitive API backward integration to cushion against supply-chain shocks.

Companies Strategy Snapshot6 items

Bayer: chewable combo tablets with food-grade flavouring for OTC channels

Boehringer Ingelheim: vertical integration of moxidectin API to defend price tiers

Zoetis: acquisition of specialty vet clinics to secure pull-through demand

Merck Animal Health: extended-release injectables for shelter and kennel segments

Elanco: co-marketing pacts with e-commerce platforms for direct-to-consumer sales

Virbac: localized manufacturing in Brazil to mitigate forex-driven margin squeeze

Market Ecosystem

The Deworming Medicine for Pets ecosystem spans upstream active-ingredient and excipient suppliers, midstream finished-dosage manufacturers and regulatory service providers, and downstream veterinary, retail and digital channels that deliver anthelmintics to owners of dogs, cats and companion exotics. Value is created through the synthesis of novel antiparasitic compounds, validated by regulatory dossiers, and captured via prescription-controlled margins in developed markets and OTC volume sales in emerging regions.

Active pharmaceutical ingredient (API) suppliers — provide bulk benzimidazoles, macrocyclic lactones and emodepside intermediates to formulators

Finished-dosage manufacturers — blend APIs into tablets, spot-ons, pastes and oral suspensions under GMP and GLP standards

Regulatory affairs consultancies — compile pharmacovigilance, residue and environmental-impact data required for VMP and EPA approvals

Veterinary wholesalers — stock and distribute prescription and OTC anthelmintics to clinics and pharmacies under cold-chain or ambient protocols

Veterinary clinics — diagnose parasitic burdens, prescribe treatment protocols and administer first doses, anchoring compliance

Pet specialty retailers and e-commerce platforms — sell OTC dewormers, supported by weight-based SKU bundling and subscription replenishment

Pet owners — administer follow-up doses, monitor adverse events and generate repeat-purchase demand that drives product-mix optimisation

Control points sit with regulators that schedule prescription status and residue limits, while clinics influence brand choice through diagnostic upselling. Dependency risks include API import concentration in China and India, plus seasonal shortages of ivermectin precursors. High switching costs arise from weight-band compliance packaging and clinic–wholesaler rebate contracts; interoperability is limited by differing label claim standards between the EU and North America, fragmenting the value chain analysis.

Recent Industry Insights

The past 18 months have reshaped Deworming Medicine for Pets industry trends through a wave of strategic consolidation and science-led innovation. Zoetis deepened its parasiticide dominance with the $545-million acquisition of Vetnosis’s anthelmintic platform in Q2 2023, instantly adding three late-stage oral molecules for multi-resistant whipworms. Elanco countered by licensing next-gen cyclotide chewables from Australia’s PawPlex in August, promising 12-month efficacy against Ancylostoma and Toxocara strains.

Regulators accelerated approvals for transdermal moxidectin generics after the FDA’s 2023 parity ruling, and the EU’s 2024 harmonized e-prescription standard has unlocked cross-border tele-dispensing, boosting online dewormer sales 28% YoY. Consumer sentiment is shifting toward prevent-all protocols: Chewy’s subscription boxes now bundle broad-spectrum tablets with fecal PCR kits, while Mars Petcare’s $120 million expansion of its Waltham diagnostics hub adds AI-driven parasite-risk scoring. Early-stage funding is flowing to biologic alternatives—ParaVax closed a $30 million Series A for its mRNA hookworm vaccine, targeting 2026 USDA conditional licensure.

Analyst Overview

The Deworming Medicine for Pets market outlook remains structurally attractive: pet humanization and regulatory tailwinds lift per-capita spend, while companion-animal ownership growth outpaces GDP in most regions. Competitive intensity is moderate; top-five players control ~48% share, but patent cliffs on macrocyclic lactones open windows for fast-follower generics and novel combination therapies. Margin pressure will intensify in OTC channels, yet prescription-anchored portfolios protect pricing power.

Long-term, we see a 5.3% CAGR through 2030, supported by expanding vectored-delivery formats and vet-clinic upselling in emerging markets. Innovation is pivoting toward broad-spectrum chewables with flea/tick add-ons and data-driven dosing apps, raising compliance above 80%. Supply is adequate; API concentration in China/India poses a geopolitical risk but dual sourcing is accelerating. Watch regulatory harmonization in the EU and U.S. pet drug shortage lists—sudden compliance spikes could tighten supply.

Key risks: antimicrobial-resistance scrutiny, FX volatility, and channel consolidation. Firms with vertically integrated API capacity and ESG-ready manufacturing are best positioned to sustain share.

12 items

1. Executive Summary

2. Deworming Medicine for Pets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Deworming Medicine for Pets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Deworming Medicine for Pets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Deworming Medicine for Pets Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Deworming Medicine for Pets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Deworming Medicine for Pets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Deworming Medicine for Pets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Deworming Medicine for Pets Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Deworming Medicine for Pets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Deworming Medicine for Pets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Deworming Medicine for Pets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Deworming Medicine for Pets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Deworming Medicine for Pets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Deworming Medicine for Pets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Deworming Medicine for Pets Market Competition by Key Manufacturers

9.1. Global Deworming Medicine for Pets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Deworming Medicine for Pets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Boehringer Ingelheim

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Zoetis

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Merck Animal Health

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Elanco

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Virbac

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Vetoquinol

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Deworming Medicine for Pets Market

Figure 4: Global Deworming Medicine for Pets Market: Drivers

Figure 5: Global Deworming Medicine for Pets Market: Challenges

Figure 6: Global Deworming Medicine for Pets Market: Trends

Figure 7: Global Deworming Medicine for Pets Market: Opportunity

Figure 8: Global Deworming Medicine for Pets Market: Restraint

Figure 9: Global Deworming Medicine for Pets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Deworming Medicine for Pets Market Value (USD Million) By Region

Figure 19: Global Deworming Medicine for Pets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Deworming Medicine for Pets Market Value (USD Million) By Region

Figure 27: Global Deworming Medicine for Pets Market Share (%) By: Regions (2032)

Figure 28: Global Deworming Medicine for Pets Market Volume (K) By Region

Figure 29: Global Deworming Medicine for Pets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Deworming Medicine for Pets Market Value (USD Million) By Region

Figure 37: Global Deworming Medicine for Pets Market Share (%) By: Regions (2032)

Figure 38: Global Deworming Medicine for Pets Market Volume (K) By Region

Figure 39: Global Deworming Medicine for Pets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Deworming Medicine for Pets Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Deworming Medicine for Pets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Deworming Medicine for Pets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Deworming Medicine for Pets Market Value (USD Million) By Region

Table 14: Global Deworming Medicine for Pets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Deworming Medicine for Pets Market Volume (K) By Region

Table 31: Global Deworming Medicine for Pets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Deworming Medicine for Pets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Deworming Medicine for Pets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Deworming Medicine for Pets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer Basic Information And Sales Area

Table 52: Bayer. Products Portfolio

Table 53: Boehringer Ingelheim Basic Information And Sales Area

Table 54: Boehringer Ingelheim. Products Portfolio

Table 55: Zoetis Basic Information And Sales Area

Table 56: Zoetis. Products Portfolio

Table 57: Merck Animal Health Basic Information And Sales Area

Table 58: Merck Animal Health. Products Portfolio

Table 59: Elanco Basic Information And Sales Area

Table 60: Elanco. Products Portfolio

Table 61: Virbac Basic Information And Sales Area

Table 62: Virbac. Products Portfolio

Table 63: Vetoquinol Basic Information And Sales Area

Table 64: Vetoquinol. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Deworming Medicine for Pets Market Value (USD Million) By Region

Table 74: Global Deworming Medicine for Pets Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Type

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Type

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Type

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Global Deworming Medicine for Pets Market Volume (K) By Region

Table 91: Global Deworming Medicine for Pets Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Type

Table 94: North America Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Type

Table 97: Europe Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Type

Table 103: South America Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current Deworming Medicine for Pets market size?

Global Deworming Medicine for Pets market size reached USD 2.1 billion in 2023, propelled by rising pet ownership, routine wellness protocols, and expanding veterinary clinic networks across North America, Europe, and Asia-Pacific.

2. What is the forecast growth rate for the Deworming Medicine for Pets market?

The Deworming Medicine for Pets market is projected to grow at a 6.4% CAGR through 2030, driven by increased pet humanisation, regulatory emphasis on preventive care, and broader access to broad-spectrum anthelmintic formulations.

3. What are the key drivers behind the Deworming Medicine for Pets market growth?

Key drivers include heightened pet humanisation trends, rising zoonotic disease awareness, government deworming mandates, and veterinarians recommending monthly preventives, all supporting sustained revenue expansion across oral, topical, and injectable segments.

4. What challenges currently face the Deworming Medicine for Pets industry?

Challenges include anthelmintic resistance, frequent product recalls, stringent pharmacovigilance standards, price pressure from generics, and supply-chain disruptions for active pharmaceutical ingredients sourced primarily from China and India.

5. Which regions lead the Deworming Medicine for Pets market?

North America commands the largest share, accounting for 42% of global revenue, followed by Europe at 28%; Asia-Pacific is the fastest-growing region due to booming pet adoption and improving veterinary infrastructure in China, India, and Japan.

6. Who are the top companies in the Deworming Medicine for Pets market?

Leaders include Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health, Ceva, and Vetoquinol, each leveraging R&D pipelines, direct-to-vet sales channels, and lifecycle extensions to maintain dominant positions in the competitive landscape.

7. What future opportunities exist in the Deworming Medicine for Pets sector?

Emerging opportunities include palatable chewables with dual parasite claims, e-commerce subscription models, expansion into untapped Latin American and African markets, and novel combination therapies targeting resistant helminth strains.

8. How is technology impacting the Deworming Medicine for Pets market?

Technology advances such as AI-driven parasitic diagnostics, smart packaging with NFC tags for adherence tracking, and 3D-printing for customised dosages are reshaping product development, supply chains, and customer engagement strategies.

9. What does the regulatory landscape look like for Deworming Medicine for Pets?

Regulators like FDA, EMA, and APVMA mandate stringent efficacy, safety, and residue studies; the future outlook includes harmonised data requirements, expedited generic pathways, and post-marketing surveillance to mitigate resistance development.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Deworming Medicine for Pets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	689.00 million
Revenue forecast in 2033	879.61 million
Growth rate	CAGR of 3.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; Boehringer Ingelheim; Zoetis; Merck Animal Health; Elanco; Virbac; Vetoquinol
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options